Troglitazone and liver injury: in search of answers (Q36013357)

11 August 2017

1 reference

title

Troglitazone and liver injury: in search of answers (English)

1 reference

11 August 2017

Mario Chojkier

1

1 reference

PubMed ID

15657914

11 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

11 August 2017

1 reference

11 August 2017

41

1 reference

11 August 2017

2

1 reference

11 August 2017

237-246

1 reference

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

11 August 2017

1 reference

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

21 January 2018

1 reference

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

21 January 2018

1 reference

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States

21 January 2018

1 reference

Did this drug cause my patient's hepatitis?

21 January 2018

1 reference

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.

21 January 2018

1 reference

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

6 alpha-glucuronidation of hyodeoxycholic acid by human liver, kidney and small bowel microsomes

21 January 2018

1 reference

6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes

21 January 2018

1 reference

D-Galactosamine hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice.

21 January 2018

1 reference

Troglitazone-induced liver failure: a case study

21 January 2018

1 reference

7 January 2021

Mechanisms of troglitazone hepatotoxicity

1 reference

7 January 2021

Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes

1 reference

7 January 2021

Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide.

1 reference

7 January 2021

Mitochondrial dysfunction in the elderly: possible role in insulin resistance

1 reference

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

7 January 2021

Causation of type 2 diabetes -- the Gordian knot unravels

1 reference

7 January 2021

Troglitazone (Rezulin) and hepatic injury

1 reference

7 January 2021

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

7 January 2021

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

7 January 2021

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

7 January 2021

Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.

1 reference

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

7 January 2021

Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione

1 reference

7 January 2021

Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin

1 reference

7 January 2021

Fatal hepatotoxicity associated with troglitazone

1 reference

7 January 2021

A Japanese case of liver dysfunction after 19 months of troglitazone treatment

1 reference

7 January 2021

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

1 reference

7 January 2021

Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination

1 reference

7 January 2021

Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group

1 reference

7 January 2021

Troglitazone-associated hepatotoxicity treated successfully with steroids

1 reference

7 January 2021

Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings

1 reference

7 January 2021

Rapid-onset subfulminant liver failure associated with troglitazone

1 reference

7 January 2021

Hepatic injury due to troglitazone

1 reference

7 January 2021

Severe but reversible hepatitis induced by troglitazone

1 reference

7 January 2021

An autopsy case of troglitazone-induced fulminant hepatitis

1 reference

7 January 2021

Severe hepatotoxicity associated with troglitazone

1 reference

7 January 2021

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

1 reference

7 January 2021

Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus

1 reference

7 January 2021

Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone

1 reference

7 January 2021

Drug-induced liver injury: mechanisms and test systems.

1 reference

7 January 2021

Drug-induced liver disorders: implications for drug development and regulation

1 reference

7 January 2021

Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone

1 reference

7 January 2021

Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone

1 reference

7 January 2021

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

1 reference

7 January 2021

Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge

1 reference

7 January 2021

Diabetes increases the risk of acute hepatic failure

1 reference

7 January 2021

A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents

1 reference

7 January 2021

Risk of Unexplained Acute Liver Failure in Diabetes Mellitus—Reply

1 reference

7 January 2021

Subacute liver failure in obese women

1 reference

7 January 2021

Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells

1 reference

7 January 2021

Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile

1 reference

7 January 2021

Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.

1 reference

7 January 2021

Clinical pharmacokinetics of troglitazone

1 reference

7 January 2021

Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency

1 reference

7 January 2021

Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites.

1 reference

7 January 2021

Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.

1 reference

7 January 2021

Mechanisms of hepatotoxicity

1 reference

7 January 2021

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

1 reference

7 January 2021

Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones

1 reference

7 January 2021

Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone

1 reference

7 January 2021

Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice

1 reference

7 January 2021

Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways

1 reference

7 January 2021

Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats.

1 reference

7 January 2021

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats

1 reference

7 January 2021

Troglitazone prevents fatty changes of the liver in obese diabetic rats.

1 reference

7 January 2021

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

1 reference

7 January 2021

Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial

1 reference

7 January 2021

Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes

1 reference

7 January 2021

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

1 reference

7 January 2021

Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression

1 reference

7 January 2021

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

1 reference

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

7 January 2021

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

1 reference

7 January 2021

Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes

1 reference

7 January 2021

Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity

1 reference

7 January 2021

Inhibition of oxidation of low density lipoprotein by troglitazone

1 reference

7 January 2021

Another potential use of troglitazone in noninsulin-dependent diabetes mellitus

1 reference

7 January 2021

Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus

1 reference

7 January 2021

Acute troglitazone action in isolated perfused rat liver

1 reference

7 January 2021

Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions

1 reference

7 January 2021

Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver

1 reference

7 January 2021

Stimulation of bile acid 6 alpha-hydroxylation by rifampin

1 reference

7 January 2021

Humanized xenobiotic response in mice expressing nuclear receptor SXR.

1 reference

7 January 2021

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

1 reference

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

7 January 2021

Evaluation of abnormal liver-enzyme results in asymptomatic patients

1 reference

7 January 2021

The mechanism of elevated alkaline phosphatase activity after bile duct ligation in the rat

1 reference

7 January 2021

An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

1 reference

7 January 2021

Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes

1 reference

7 January 2021

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

1 reference

7 January 2021

Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c

1 reference

7 January 2021

Interleukin-1 receptor type I gene-deficient bile duct-ligated mice are partially protected against endotoxin

1 reference

7 January 2021

An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis

1 reference

7 January 2021

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

1 reference

7 January 2021

Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis

1 reference

7 January 2021

Prostaglandin D(2), its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells

1 reference

7 January 2021

Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes

1 reference

7 January 2021

Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines

1 reference

7 January 2021

The pathophysiology of mitochondrial cell death

1 reference

7 January 2021

Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes

1 reference

7 January 2021

Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway

1 reference

7 January 2021

Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes

1 reference

7 January 2021

Toxic effect of troglitazone on cultured rat hepatocytes

1 reference

7 January 2021

Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells

1 reference

7 January 2021

Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes

1 reference

7 January 2021

Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes

1 reference

7 January 2021

Cryopreservation of hepatocytes: a review of current methods for banking.

1 reference

7 January 2021

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

1 reference

7 January 2021

Preferential distribution of apoptotic bodies in acinar zone 3 of normal human and rat liver

1 reference

7 January 2021

Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas.

1 reference

7 January 2021

Concanavalin A-induced liver injury triggers hepatocyte proliferation

1 reference

7 January 2021

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

1 reference

7 January 2021

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

7 January 2021

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

7 January 2021

Mitochondrial abnormalities in non-alcoholic steatohepatitis

1 reference

7 January 2021

Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy

1 reference

7 January 2021

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

7 January 2021

Hepatic lipocytes: the principal collagen-producing cells of normal rat liver

1 reference

7 January 2021

Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression

1 reference

7 January 2021

Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis.

1 reference

7 January 2021

Apoptosis: the nexus of liver injury and fibrosis.

1 reference

7 January 2021

Peroxisome proliferator-activated receptors and hepatic stellate cell activation

1 reference

7 January 2021

Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells

1 reference

7 January 2021

Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies

1 reference

7 January 2021

p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone

1 reference

7 January 2021

Genetics. SNP-ing drugs to size

1 reference

7 January 2021

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

7 January 2021

CYP3A genetics in drug metabolism

1 reference

7 January 2021

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

1 reference

7 January 2021

The genetic determinants of the CYP3A5 polymorphism

1 reference

7 January 2021

Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients

1 reference

7 January 2021

Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved

1 reference

7 January 2021

A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20567

1 reference

11 August 2017

1 reference

PubMed ID

15657914